In this discussion with a US-based KOL, we dive into in-depth opinions on the approved agents and late-stage pipeline drugs in the IBD market. The KOL discusses the various unmet needs in the indication and speaks on the future of the market, where biologics and orals will compete head-to-head, and which one is likely to come out on top. The impact of biosimilars and promising pipeline agents is also discussed here. 

This interview was conducted on 8 November 2023. 

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only). 

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.